Literature DB >> 22016559

Downregulation of RNAIII in vancomycin-intermediate Staphylococcus aureus strains regardless of the presence of agr mutation.

Chulmin Park1, Na-Young Shin1, Ji-Hyun Byun1, Hyun-Ho Shin1, Eun-Young Kwon1, Su-Mi Choi2, Si-Hyun Kim2, Jae-Chul Kwon2, Sun Hee Park2, Jung-Hyun Choi2, Jin-Hong Yoo2, Jae Il Yoo3, Gyung Tae Chung3, Dong-Gun Lee2.   

Abstract

Reduced vancomycin susceptibility in Staphylococcus aureus can cause serious problems relating to treatment failure and persistent infection. We investigated vancomycin susceptibility, genetic relationships and transcriptional changes of the accessory gene regulator (agr) in vancomycin-intermediate S. aureus (VISA) strains isolated from South Korea compared with vancomycin-susceptible S. aureus (VSSA) strains. Molecular characterization, population analysis profiling, agr sequencing and transcriptional profiling of RNAIII by real-time RT-PCR were performed. Of 16 VISA strains tested, eight exhibited ST5, agr II and type II SCCmec. The others exhibited ST239, agr I and type III SCCmec. A point mutation in AgrA (Asp8Gly or Ile238Lys) was found in only five VISA strains; no mutations were detected in the other strains. However, RNAIII levels markedly decreased in all VISA strains (mean of 1.39-fold change) compared with the VSSA strains (31.51-fold change) in late-exponential phases (P<0.0001). The downregulation of RNAIII could be an important genetic event in the VISA strains, regardless of the presence or absence of the agr mutation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22016559     DOI: 10.1099/jmm.0.035204-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  7 in total

1.  Early agr activation correlates with vancomycin treatment failure in multi-clonotype MRSA endovascular infections.

Authors:  Wessam Abdelhady; Liang Chen; Arnold S Bayer; Kati Seidl; Michael R Yeaman; Barry N Kreiswirth; Yan Q Xiong
Journal:  J Antimicrob Chemother       Date:  2015-01-05       Impact factor: 5.790

2.  Decreased vancomycin susceptibility in Staphylococcus aureus caused by IS256 tempering of WalKR expression.

Authors:  Christopher R E McEvoy; Brian Tsuji; Wei Gao; Torsten Seemann; Jessica L Porter; Kenneth Doig; Dung Ngo; Benjamin P Howden; Timothy P Stinear
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

3.  First report of vancomycin-intermediate resistance in sequence type 72 community genotype methicillin-resistant Staphylococcus aureus.

Authors:  Doo Ryeon Chung; Jin Yang Baek; Hyun Ah Kim; Min Hee Lim; So Hyun Kim; Kwan Soo Ko; Cheol-In Kang; Kyong Ran Peck; Nam Yong Lee; Jae-Hoon Song
Journal:  J Clin Microbiol       Date:  2012-05-02       Impact factor: 5.948

4.  Phenotypic and Molecular Characterisation of Staphylococcus Aureus with Reduced Vancomycin Susceptibility Derivated in Vitro.

Authors:  Jia Xu; Long Pang; Xiao Xue Ma; Jian Hu; Yuan Tian; Ya Li Yang; Dan Dan Sun
Journal:  Open Med (Wars)       Date:  2018-10-22

5.  Phenotypic Characteristics of Vancomycin-Non-Susceptible Staphylococcus aureus.

Authors:  Auttawit Sirichoat; Sujintana Wongthong; Ratdawan Kanyota; Ratree Tavichakorntrakool; Aroonwadee Chanawong; Jariya Umka Welbat; Aroonlug Lulitanond
Journal:  Jundishapur J Microbiol       Date:  2016-01-02       Impact factor: 0.747

6.  Genomic insights on heterogeneous resistance to vancomycin and teicoplanin in Methicillin-resistant Staphylococcus aureus: A first report from South India.

Authors:  Yamuna Devi Bakthavatchalam; Priyanka Babu; Elakkiya Munusamy; Hariharan Triplicane Dwarakanathan; Priscilla Rupali; Marcus Zervos; Peter John Victor; Balaji Veeraraghavan
Journal:  PLoS One       Date:  2019-12-30       Impact factor: 3.240

7.  Comparative Analysis of Virulence and Toxin Expression of Vancomycin-Intermediate and Vancomycin-Sensitive Staphylococcus aureus Strains.

Authors:  Ye Jin; Xiao Yu; Shuntian Zhang; Xiaoyang Kong; Weiwei Chen; Qixia Luo; Beiwen Zheng; Yonghong Xiao
Journal:  Front Microbiol       Date:  2020-10-30       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.